PROPRANOLOL LAURATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H21NO2.C12H24O2
Molecular Weight	459.6612
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCC(O)=O.CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1

InChI

InChIKey=CAWRJDLZCQEKMX-UHFFFAOYSA-N

InChI=1S/C16H21NO2.C12H24O2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;1-2-3-4-5-6-7-8-9-10-11-12(13)14/h3-9,12,14,17-18H,10-11H2,1-2H3;2-11H2,1H3,(H,13,14)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25198737 https://www.ncbi.nlm.nih.gov/pubmed/2865152

Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Propranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Also is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; for the prophylaxis of common migraine headache. In addition, is used to improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Due to the high penetration across the blood–brain barrier, propranolol causes sleep disturbances such as insomnia and vivid dreams, and nightmares. Dreaming (rapid eye movement sleep, REM) was reduced and increased awakening.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6121573	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
hypertension 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf	Primary	Approved 8429	INDERAL LA Approved Use Propranolol hydrochloride extended-release capsules are indicated for the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules are not indicated for the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of a common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Launch Date 1987
Angina pectoris 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf	Primary	Approved 8429	INDERAL LA Approved Use Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Launch Date 1987
Migraine 103 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf	Preventing	Approved 8429	INDERAL LA Approved Use Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Launch Date 1987
Hypertrophic subaortic stenosis 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf	Primary	Approved 8429	INDERAL LA Approved Use Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Launch Date 1987

C_max

Value	Dose	Analyte	Population
147 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, sublingual dose: 40 mg route of administration: Sublingual experiment type: SINGLE co-administered:	PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
41 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
161 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
26 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPRANOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
47 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, sublingual dose: 40 mg route of administration: Sublingual experiment type: SINGLE co-administered:		PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
79 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, sublingual dose: 40 mg route of administration: Sublingual experiment type: SINGLE co-administered:		PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.41 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9698776/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PROPRANOLOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 911 CYP2B6 810 CYP1A1 110 CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 ALDH1 40 OCT1 512 OCT2 647 BSEP 402 MRP2 383 MRP3 157 MRP4 204 OATP1B1 788 OATP1B3 706 OATP2B1 123 BCRP 699 NTCP 34 Cav1.2 45 Nav1.5 97	CYP1A2 1054 CYP2C19 991 CYP1A1 349 CYP2A6 543 CYP2B6 664 CYP2E1 667 CYP2C8 693 CYP4A11 119 OCT2 355 UGT 192 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A9 380 UGT2B4 249 UGT2B7 389 UGT2B10 127 UGT2B15 203 SULT1A1 29 SULT1A3 27 SULT1E1 17 SULT2A1 24 MRP2 205 MRP3 50 MRP4 77 BCRP 561

Drug as perpetrator

Target	Modality	Activity
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18457386/, https://pubmed.ncbi.nlm.nih.gov/23956101/	likely [IC50 >133 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://pubmed.ncbi.nlm.nih.gov/23571415/	likely
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://pubmed.ncbi.nlm.nih.gov/23571415/	likely
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	likely
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	no [IC50 >10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	no [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMjcifX0%3D	no [IC50 >10 uM]
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22961681/, https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >1000 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	no
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
ALDH1 40	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2NzEifX0%3D	yes [Activation 28.1838 uM]
OCT2 648	inhibitor 3277 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/19251820/, https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 189 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/8474022/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	yes [IC50 4 uM]
NTCP 35	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10565843/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Mjg3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	yes [Inhibition 5.5 uM]
CYP1A1 218	inhibitor 3277 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/8474022/	yes
CYP2D6 1891	inhibitor 3277 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/9342584/	yes
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8	major		yes (co-administration study) Comment: Coadminstration of CYP1A2 inhibitors increased Propranolol plasma concentration. Coadministration of CYP1A2 inducers decreased Propranolol plasma concentration. Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8
CYP2D6 1217	substrate 3367 Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8	major		yes (co-administration study) Comment: Coadminstration of CYP2D6 inhibitors increased Propranolol plasma concentration. Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8
CYP2C19 991	substrate 3367 Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8	minor		yes (co-administration study) Comment: Coadminstration of CYP2C19 inhibitors increased Propranolol plasma concentration. Coadministration of CYP2C19 inducers decreased Propranolol plasma concentration. Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf#page=5 Page: (Label) 5, 7-8
CYP1A1 349	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
CYP4A11 119	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10945865/	no
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	no	R-plopranolol glucuronide 3
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	no	S-plopranolol glucuronide 3
SULT2A1 24	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15748705/	no	4-hydroxypropranolol 3
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	no
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	no
UGT2B10 127	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MTYwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19	no
UGT2B15 203	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	no
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	weak	R-plopranolol glucuronide 3
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	weak	S-plopranolol glucuronide 3
MRP4 77	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	weak	R-plopranolol glucuronide 3
MRP4 77	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	weak	S-plopranolol glucuronide 3
OCT2 355	substrate 3367 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/19251820/	yes [Km 11.8 uM]
MRP3 50	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	yes [Km 154 uM]	R-plopranolol glucuronide 3
MRP3 50	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28850245/	yes [Km 434 uM]	S-plopranolol glucuronide 3
SULT1A1 29	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15748705/	yes	4-hydroxypropranolol 3
SULT1A3 27	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15748705/	yes	4-hydroxypropranolol 3
SULT1E1 17	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15748705/	yes	4-hydroxypropranolol 3
UGT 192	substrate 3367 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000525666, https://pubmed.ncbi.nlm.nih.gov/21098645/	yes
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	yes
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	yes
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18936551/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Cav1.2 49	inhibitor 1626 Sources: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/jat.2784, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxOTQwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19
Nav1.5 100	inhibitor 1626 Sources: https://academic.oup.com/cardiovascres/article/91/1/53/333710, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxOTgwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI3In19
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/16150441/, https://academic.oup.com/cardiovascres/article/91/1/53/333710

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8499	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8499
ChemicalBook	CB0875381	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0875381
ChemicalBook	CB63039539	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB63039539
MolPort	MolPort-001-794-623	https://www.molport.com/shop/molecule-link/MolPort-001-794-623
eMolecules	735071	https://www.emolecules.com/cgi-bin/more?vid=735071

PubMed

Title	Date	PubMed
Severe bradycardia after neostigmine in a patient taking propranolol to control paroxysmal atrial tachycardia.	1975 Feb	1115373
[Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)].	1976 Jul	11153
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].	2000 Nov	11218852
Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.	2000 Oct	11129949
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.	2001 Feb	11216977
Idiopathic sustained left ventricular tachycardia in pediatric patients.	2001 Feb	11207998
Periovulatory changes in catfish ovarian oestradiol-17beta, oestrogen-2-hydroxylase and catechol-O-methyltransferase during GnRH analogue-induced ovulation and in vitro induction of oocyte maturation by catecholoestrogens.	2001 Feb	11182761
Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts.	2001 Feb	11181755
Pharmacologic therapy for portal hypertension.	2001 Feb	11177691
Pharmacologic management of atrial fibrillation: current therapeutic strategies.	2001 Feb	11174354
Epinephrine yields translocation of lymphocytes to the lung.	2001 Feb	11170785
Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells.	2001 Feb	11160630
beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells.	2001 Feb	11159726
Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats.	2001 Feb	11158985
beta-Adrenoceptor and nNOS-derived NO interactions modulate hypoglycemic pial arteriolar dilation in rats.	2001 Feb	11158952
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand.	2001 Feb	11137886
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.	2001 Feb 1	11164853
Comparison of spontaneous and noradrenaline-evoked non-selective cation channels in rabbit portal vein myocytes.	2001 Feb 1	11158276
Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality.	2001 Feb 13	11171800
Sympathetic control of nasal blood flow in the rat mediated by alpha(1)-adrenoceptors.	2001 Feb 16	11226401
Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists.	2001 Feb 16	11226398
Correlation of the electrical and intrinsic optical signals in the chicken spreading depression phenomenon.	2001 Feb 16	11166945
Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats.	2001 Feb 2	11166291
[Availability of antidotes in French emergency medical aid units].	2001 Feb 3	11229303
Modulation of a 40-kDa catecholamine regulated protein by dopamine receptor antagonists.	2001 Feb 9	11173065
Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics.	2001 Jan	11211903
Evidence for the binding of beta-adrenoceptor blockers to microsomal Na+/K+-ATPase in guinea pig heart preparations.	2001 Jan	11201505
Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.	2001 Jan	11191841
Successful use of propranolol in migraine associated with electroconvulsive therapy.	2001 Jan	11168610
beta(1)-Adrenoceptors compensate for beta(3)-adrenoceptors in ileum from beta(3)-adrenoceptor knock-out mice.	2001 Jan	11159692
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.	2001 Jan	11156573
Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study.	2001 Jan	11141226
Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants.	2001 Jan	11136494
Ventricular activation during sympathetic imbalance and its computational reconstruction.	2001 Jan	11133921
Adrenergic receptor activated ion transport in human fetal retinal pigment epithelium.	2001 Jan	11133877
Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.	2001 Jan	11133229
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.	2001 Jan	11123227
Role of PAG in the antinociception evoked from the medial or central amygdala in rats.	2001 Jan 1	11226714
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia.	2001 Jan 1	11123332
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.	2001 Jan 12	11150484
Colon and anal sphincter contractions evoked by microstimulation of the sacral spinal cord in cats.	2001 Jan 19	11166684
Effects of mono-, di- and tri-hydroxybenzoic acids on the nitrosation of propranolol: structure-activity relationship.	2001 Jan 25	11152975
Effect of carvedilol on atrioventricular conduction in the ischemic heart.	2001 Jan 26	11165226
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.	2001 Jan 26	11164765
Ion-exchange fibers and drugs: an equilibrium study.	2001 Jan 29	11166422
Misrepresentation and miscommunication of teratogenic risk of drugs; analysis of three highly publicized international cases.	2001 Jan-Feb	11137372
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.	2001 Jan-Feb	11123125
Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis.	2001 Mar	11228188
Erythroid carbonic anhydrase and hsp70 expression in chick embryonic development: role of cAMP and hypoxia.	2001 Mar	11171668
Central corticotropin releasing factor (CRF) and adrenergic receptors mediate hemodynamic responses to cocaine.	2001 Mar 2	11222986

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: The usual initial dosage is 80 mg capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once. Angina Pectoris: Starting with 80 mg capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. Migraine: The initial oral dose is 80 mg capsules once daily. The usual effective dose range is 160 to 240 mg once daily. Hypertrophic Subaortic Stenosis: The usual dosage is 80 to 160 mg capsules once daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

PROPRANOLOL LAURATE

Common Name

English

2-PROPANOL, 1-((1-METHYLETHYL)AMINO)-3-(1-NAPHTHALENYLOXY)-, DODECANOATE (SALT)

Systematic Name

English

PROPRANOLOL LAURATE, (±)-

Common Name

English

DODECANOIC ACID, COMPD. WITH 1-((1-METHYLETHYL)AMINO)-3-(1-NAPHTHALENYLOXY)-2-PROPANOL (1:1)

Systematic Name

English

Code System Code Type Description

FDA UNII

KY69W91A2F

Created by admin on Sat Dec 16 08:34:30 GMT 2023 , Edited by admin on Sat Dec 16 08:34:30 GMT 2023

PRIMARY

CAS

138656-55-0

Created by admin on Sat Dec 16 08:34:30 GMT 2023 , Edited by admin on Sat Dec 16 08:34:30 GMT 2023

PRIMARY

PUBCHEM

3036087

Created by admin on Sat Dec 16 08:34:30 GMT 2023 , Edited by admin on Sat Dec 16 08:34:30 GMT 2023

PRIMARY

EPA CompTox

DTXSID20930178

Created by admin on Sat Dec 16 08:34:30 GMT 2023 , Edited by admin on Sat Dec 16 08:34:30 GMT 2023

PRIMARY

SUBSTANCE RECORD


					KY69W91A2F

PROPRANOLOL LAURATE

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25198737 https://www.ncbi.nlm.nih.gov/pubmed/2865152

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018553s037lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25198737 https://www.ncbi.nlm.nih.gov/pubmed/2865152

C_max

T_1/2

Drug as perpetrator